Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Therapeutics

Volumn 34, Issue 9, 2012, Pages

  Lewin, Andrew J ^a   Arvay, Lisa ^b   Liu, Dacheng ^b   Patel, Sanjay ^c   von Eynatten, Maximilian ^d   Woerle, Hans Juergen ^d  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Add on therapy; Dipeptidyl peptidase 4 inhibitor; Linagliptin; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; LINAGLIPTIN; PLACEBO; SULFONYLUREA;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOGLYCEMIA; INTERVIEW; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 84866183265     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.07.008     Document Type: Article

References (49)

1. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258. UK Prospective Diabetes Study (UKPDS) Group.
2. Festa A., Williams K., D'Agostino R., et al. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006, 55:1114-1120.
3. Festa A., Williams K., Hanley A.J., Haffner S.M. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 2008, 57:1638-1644.
4. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
5. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
6. Garber A.J., Duncan T.G., Goodman A.M., et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997, 103:491-497.
7. McCormack J., Johns K., Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005, 173:502-504.
8. Seino S., Takahashi H., Takahashi T., Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab 2012, 14(Suppl 1):9-13.
9. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
10. Asche C.V., McAdam-Marx C., Shane-McWhorter L., et al. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:638-645.
11. Gangji A.S., Cukierman T., Gerstein H.C., et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30:389-394.
12. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
13. Korytkowski M.T. Sulfonylurea treatment of type 2 diabetes mellitus:focus on glimepiride. Pharmacotherapy 2004, 24:606-620.
14. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
15. Drucker D.J. The role of gut hormones in glucose homeostasis. J Clin Invest 2007, 117:24-32.
16. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7-18.
17. Thomas L., Eckhardt M., Langkopf E., et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase-4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008, 325:175-182.
18. Blech S., Ludwig-Schwellinger E., Grafe-Mody E.U., et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010, 38:667-678.
19. Heise T., Graefe-Mody E.U., Huttner S., et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009, 11:786-794.
20. Hollander P.A., Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010, 122:71-80.
21. Graefe-Mody U., Friedrich C., Port A., et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011, 13:939-946.
22. Del Prato S., Barnett A.H., Huisman H., et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial. Diabetes Obes Metab 2011, 13:258-267.
23. Taskinen M.R., Rosenstock J., Tamminen I., et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:65-74.
24. Owens D.R., Swallow R., Dugi K.A., Woerle H.J. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study(1). Diabet Med 2011, 28:1352-1361.
25. Haak T., Meinicke T., Jones R., et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012, 14:565-574.
26. Gomis R., Espadero R.M., Jones R., et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:653-661.
27. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997, 277:925-926. World Medical Association declaration of Helsinki.
28. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. J Postgrad Med 2001, 47:199-203.
29. Molzon J.A., Giaquinto A., Lindstrom L., et al. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health. Clin Pharmacol Ther 2011, 89:503-512.
30. Armstrong R.A., Slade S.V., Eperjesi F. An introduction to analysis of variance (ANOVA) with special reference to data from clinical experiments in optometry. Ophthalmic Physiol Opt 2000, 20:235-241.
31. Kenward M.G., Molenberghs G. Last observation carried forward: a crystal ball?. J Biopharm Stat 2009, 19:872-888.
32. O'Brien P.C., Zhang D., Bailey K.R. Semi-parametric and non-parametric methods for clinical trials with incomplete data. Stat Med 2005, 24:341-358.
33. Anderson R.P., Jin R., Grunkemeier G.L. Understanding logistic regression analysis in clinical reports: an introduction. Ann Thorac Surg 2003, 75:753-757.
34. Ludbrook J., Royse A.G. Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots. ANZJSurg 2008, 78:204-210.
35. Chacra A.R., Tan G.H., Apanovitch A., et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009, 63:1395-1406.
36. Hermansen K., Kipnes M., Luo E., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
37. Garber A.J., Foley J.E., Banerji M.A., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008, 10:1047-1056.
38. Pratley R.E., Kipnes M.S., Fleck P.R., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009, 11:167-176.
39. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88:787-835. ix.
40. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006, 23:579-593. Clinical Guidelines Task Force of the International Diabetes Federation.
41. Stenman S., Melander A., Groop P.H., Groop L.C. What is the benefit of increasing the sulfonylurea dose?. Ann Intern Med 1993, 118:169-172.
42. Haneda M., Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrol Dial Transplant 2009, 24:338-341.
43. Krepinsky J., Ingram A.J., Clase C.M. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000, 35:500-505.
44. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011, 124:S3-S18.
45. Willemen M.J., Mantel-Teeuwisse A.K., Straus S.M., et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011, 34:369-374.
46. Schernthaner G., Barnett A.H., Emser A., et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14:470-478.
47. Tradjenta (linagliptin) tablets [prescribing Information] Accessed 2012. http://hcp.tradjenta.com/.
48. Sloan L., Newman J., Sauce C., et al. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Diabetes 2011, 60(Suppl 1):a114. Abstract.
49. Newman J., McGill J., Patel S., et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetologia 2011, 54(Suppl 1):S108.